Bioengineering Research Initiative to Develop Global Entrepreneurs
Providing Resources for Startups, Developing Entrepreneurial Talent
The Bioengineering Research initiative to Develop Global Entrepreneurs — BRiDGE℠ — expands the resources available to bioengineering startup companies founded by Duke BME faculty, PhD students, and alumni — and develops their entrepreneurial skills.
"The challenge of bridging the funding gap that Duke Engineering startups faced resonated with my career experience. My wish for BRiDGE is that meaningful ideas will emerge and develop as fledgling companies."
Alan L. Kaganov
Bridge Donor and Duke Engineering Alumnus
Our goal is to provide a bridge for young startups to cross the entrepreneurial "valley of death" to arrive at a point at which they can attract private or public investment.
Ashutosh Chilkoti began to pursue this idea shortly after becoming Duke BME chair in 2013. It became a reality in 2018 thanks to a generous gift from Duke Engineering alumnus Alan L. Kaganov and matching funds from the Pratt School of Engineering and Duke BME.
what we provide
BRiDGE provides access to 2,000-square feet of lab and office space in The Chesterfield building, expert mentoring for company leaders, and an internship program for Duke Engineering students.
The Chesterfield is a life sciences and technology research facility in downtown Durham, N.C., redeveloped from a former cigarette factory.
Our startup companies have access to:
- Leased lab benches in shared laboratory
- Leased cubicles
- Cell culture room
- Fume hood room
- Shared equipment rooms
- Shared offices and conference rooms
- Building amenities
Through partnership with Duke’s Innovation & Entrepreneurship Initiative and the Entrepreneurship @ Duke Engineering office, BRiDGE company leaders receive mentorship in the creation and refinement of their business plans.
Duke Engineering students are involved through a summer internship program. BRiDGE provides one-to-one matching funds for Duke Engineering PhD students to obtain hands-on experience with startups.
Building a patient-derived screening platform to increase the precision of personalized cancer therapies to overcome drug resistance after standard chemotherapy fails, with the added goal of developing a drug response database for cancer drug discovery.
Deep Blue Medical Advances
Developing a novel hernia mesh with integrated suture-like extensions that eliminates the key point of failure for conventional mesh fixation and provides superior anchor strength, to address the unacceptably high rate of hernia occurrence and recurrence.
Developer of technology for rapid engineering of microbial hosts enabling low-cost and faster production of specialty chemicals, flavors, fragrances, nutraceuticals, natural products, pharmaceuticals, and APIs.
Creating a non-immunogenic alternative to PEGylation that eliminates PEG antigenicity and improves drug delivery profiles.
Developing IsoTag™ by fusing an antibody-binding domain to a stimulus responsive biopolymer, to provide a fast and inexpensive alternative to the current “gold” standard, protein A chromatography.
Developing coagulation time monitoring devices and systems based on a technology invented at Zauscher Lab at Duke. This technology combines microfluidic systems with biosensors to enable extremely low sample volume requirements and on-chip pre-processing with many potential applications in the biomedical space.
Creator of 3D printed surgical implants with enhanced anatomical fit and integrative properties.